PRAX - Praxis Precision Medicines, Inc.
344.82
15.220 4.414%
Share volume: 345,884
Last Updated: 04-24-2026
Pharmaceutical Products/Pharmaceutical Preparations:
-0.11%
PREVIOUS CLOSE
CHG
CHG%
$329.60
15.22
0.05%
Fundamental analysis
41%
Profitability
35%
Dept financing
20%
Liquidity
50%
Performance
50%
Performance
5 Days
1.17%
1 Month
13.92%
3 Months
17.27%
6 Months
85.45%
1 Year
847.05%
2 Year
529.23%
Key data
Stock price
$344.82
DAY RANGE
$322.02 - $345.40
52 WEEK RANGE
$34.89 - $356.00
52 WEEK CHANGE
$847.05
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
Company detail
CEO: Marcio Souza
Region: US
Website: praxismedicines.com
Employees: 110
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Region: US
Website: praxismedicines.com
Employees: 110
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders. Its lead product candidates include PRAX-114, an extrasynaptic-preferring GABAA receptor positive allosteric modulator that is in Phase IIa clinical trial for the treatment of major depressive disorder and perimenopausal depression.
Recent news